https://japanbusinesspost.com/article/906128126-2x-avalanche-etf-now-trading Japan Business Post en PressRelease 2026-05-15T19:06:39+00:00 2x Avalanche ETF Now Trading https://japanbusinesspost.com/article/906140627-2x-sui-etf-now-trading Japan Business Post en PressRelease 2026-05-15T19:04:38+00:00 2x Sui ETF Now Trading https://japanbusinesspost.com/article/912848443-cortexforge-introduces-client-owned-operational-intelligence-category-for-organizations-outgrowing-disconnected-tools Japan Business Post en PressRelease 2026-05-15T06:00:00+00:00 CortexForge Introduces Client-Owned Operational Intelligence Category for Organizations Outgrowing Disconnected Tools https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24857291-waymark1-700x1246.png https://japanbusinesspost.com/article/912787641-bioinformatics-market-trends-investment-opportunities-and-growth-analysis-through-2033-affymetrix-inc-illumina-inc Japan Business Post en PressRelease 2026-05-14T13:05:47+00:00 Bioinformatics Market Trends, Investment Opportunities, and Growth Analysis Through 2033 | Affymetrix Inc, Illumina, Inc https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24856806-bioinformatics-market-968x968.jpeg https://japanbusinesspost.com/article/912885017-healios-k-k-to-present-at-jefferies-global-healthcare-conference Japan Business Post en PressRelease 2026-05-14T20:30:00+00:00 HEALIOS K.K. to Present at Jefferies Global Healthcare Conference https://ml.globenewswire.com/media/f656f7b5-b076-47a8-8c3c-aa6280b1ef75/small/healios-logo-horizontal-black-jpg.jpg https://japanbusinesspost.com/article/912825337-cold-solid-tumors-become-the-proving-ground-for-a-new-generation-of-engager-and-immune-priming-therapies Japan Business Post en PressRelease 2026-05-14T14:55:00+00:00 "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies https://ml.globenewswire.com/media/186a6ff0-f562-4d97-afcc-6aa99ce6be51/small/screenshot-20260422-104629-chrome-jpg.jpg https://japanbusinesspost.com/article/912787051-fda-approves-new-dosing-option-for-crysvita-burosumab-twza-in-adults-with-xlh Japan Business Post en PressRelease 2026-05-14T12:30:00+00:00 FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH https://ml.globenewswire.com/media/a3a8a24d-ccff-49c4-baf1-bf8e8a7a2551/small/img-ogp-1755267550540-png.png